Objective: To evaluate the efficacy of tadalafil 5mg+solifenacin 5mg combination in terms of lower urinary tract symptoms (LUTS) and erectile functions in benign prostate hyperplasia patients with predominant storage symptoms.
Material And Methods: Male patients over the age of 40 who presented with LUTS with predominant storage symptoms between January 2019 and December 2021 were included into the study. Daily tadalafil 5mg and solifenacin 5mg treatment were started to the patients. Overactive bladder symptom score (OABSS), international prostate symptom score (IPSS) for LUTS, and international erectile function index-erectile function (IIEF-EF) questionnaires were used for erectile function. Frequency of daily urinary frequency, frequency of nocturia, urgency and urinary incontinence were analyzed with a three-day bladder diary. Twelve weeks later, IPSS, OABSS and IIEF-EF scores of the patients were evaluated.
Results: When the symptom scores and bladder diaries of the patients before and after 12 weeks of treatment were compared, significant decrease in IPSS scores (both voiding, storage and total) (p<0.001 for each), significant increase in IIEF-EF scores (p<0.001), and significant increase in Qmax value elevation was observed. When the bladder diaries were compared, the number of daytime micturitions, the number of nocturia and the number of urgency decreased in the 12th month after tadalafil+solifenacin treatment (p<0.001).
Conclusions: The combination of tadalafil 5mg and solifenacin 5mg daily is an effective and safe treatment for male patients with storage symptoms predominant LUTS/ED.
Keywords: benign prostate hyperplasia, storage, tadalafil, solifenacin, erectile function
ABSTRACT
Objective: To evaluate the efficacy of tadalafil 5mg+solifenacin 5mg combination in terms of lower urinary tract symptoms (LUTS) and erectile functions in benign prostate hyperplasia patients with predominant storage symptoms.
Material And Methods: Male patients over the age of 40 who presented with LUTS with predominant storage symptoms between January 2019 and December 2021 were included into the study. Daily tadalafil 5mg and solifenacin 5mg treatment were started to the patients. Overactive bladder symptom score (OABSS), international prostate symptom score (IPSS) for LUTS, and international erectile function index-erectile function (IIEF-EF) questionnaires were used for erectile function. Frequency of daily urinary frequency, frequency of nocturia, urgency and urinary incontinence were analyzed with a three-day bladder diary. Twelve weeks later, IPSS, OABSS and IIEF-EF scores of the patients were evaluated.
Results: When the symptom scores and bladder diaries of the patients before and after 12 weeks of treatment were compared, significant decrease in IPSS scores (both voiding, storage and total) (p<0.001 for each), significant increase in IIEF-EF scores (p<0.001), and significant increase in Qmax value elevation was observed. When the bladder diaries were compared, the number of daytime micturitions, the number of nocturia and the number of urgency decreased in the 12th month after tadalafil+solifenacin treatment (p<0.001).
Conclusions: The combination of tadalafil 5mg and solifenacin 5mg daily is an effective and safe treatment for male patients with storage symptoms predominant LUTS/ED.
Keywords: benign prostate hyperplasia, storage, tadalafil, solifenacin, erectile function